PRRT2 and neoplasm: MEKi in combination with mTORi have shown synergistic effects in pre-clinical models of UM (Amirouchene-Angelozzi et al., 2014), and combination therapy targeting both the PI3K/mTOR and PKC/MAPK axes with a PI3K and pan-PKC inhibitor was effective in reducing xenograft tumor growth (Musi, Ambrosini, de Stanchina, & Schwartz, 2014).